Shares of NBY stock opened at $0.78 on Friday. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $12 ...

NovaBay Pharmaceuticals (NYSE:NBY) announced on Tuesday that it has received an unsolicited, non-binding offer from Refresh ...

EMERYVILLE, Calif., November 07, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. EMERYVILLE ...

加利福尼亚州埃默里维尔 - 制药公司NovaBay Pharmaceuticals, Inc. (NYSE American: NBY)今天宣布，已同意PRN Physician Recommended Nutriceuticals, ...

NovaBay had cash and cash equivalents of $0.8 million as of September 30, 2024, compared with $2.9 million as of December 31, 2023. In July 2024, the Company completed an underwritten public ...

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh ...

NovaBay Pharmaceuticals (NYSE:NBY) announced on Tuesday that it has received an unsolicited, non-binding offer from Refresh Acquisitions to purchase its Avenova brand, which it deems a "superior ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. “Avenova sales ...

Novabay(NBY)发布Q3财报，2024财年前三财季累计收入747.20万美元，去年同期累计收入为835.40万美元，同比减少10.56%。 2024财年前三财季累计净亏损601.10万美元，去年同期累计净亏损为553.20万美元，同比扩大8.66%。 本财年累计基本每股收益为-3.97美元，去年同期为-79.58美元。 公司所属行业为制药。 Novabay Pharmaceuticals, ...

View NovaBay Pharmaceuticals, Inc. (NBY) current and estimated P/E ratio data provided by Seeking Alpha.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...